Analyst
William Blair
Equibles does not estimate personal net worth.
Alex Ramsey is recorded as Analyst at William Blair. Alex Ramsey has spoken on 1 earnings call and 3 other investor events across 2 companies, most recently for Kyntra Bio, Inc. on August 13, 2026. Those appearances were for Aktis Oncology, Inc. (AKTS) and Kyntra Bio, Inc. (KYNB). The companies whose calls Alex Ramsey spoke on are classified in the Healthcare sector.
“So for the upcoming Phase 3 trial of ROXA-DUSTAT, the dosing regimen begins with 2.5 mg per kg with potential for titrating up to 3.5.”
“So our question is related to the extrapolation of lutetium-177 to actinium-225, and specifically we're wondering how the translation accounts for the recoil effect of actinium-225 and potential release of isotope from the key leader upon emission of the first alpha particle, and also how that effect could impact the…”
“So, maybe first, a bit of a theoretical question. So, you have the upcoming data at ASCO, and say you have great SUV, great bowel distribution, long-term retention.”
“So, maybe first, a bit of a theoretical question. So, you have the upcoming data at ASCO, and say you have great SUV, great bowel distribution, long-term retention.”
William Blair
Analyst
Transcript header (unverified)
AKTS
Biotechnology · Healthcare
KYNB
Biotechnology · Healthcare
